Real World Data Help Build Case For New Migraine Drugs

Sponsors working to get the CGRP inhibitors to market have turned to epidemiologic research to help identify both broad and niche opportunities for the products, which are expected to launch in 2018.

Recent epidemiologic studies should help lay the framework for marketing a new class of migraine drugs as well as provide evidence to help convince payers to adopt the new drugs over the generic standard-of-care.

There are at least seven drugs in mid- to late-stage development targeting the calcitonin gene-related peptide (CGRP) or its receptor, all vying to carve out their share of a market...

See Related Story

For more information on the CGRP inhibitor field, see Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck & Co/Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

29 May 2025

• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.